EGFR and lung adenocarcinoma: In five lung adenocarcinoma patients resistant to later-line osimertinib, recurrent mutations at <i>EGFR</i> L792 and/or L718 were identified using targeted next-generation sequencing of tissue or cell-free DNA from plasma or pleural effusion.